Delcath Systems, Inc. (NASDAQ:DCTH) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) have been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $22.50.

DCTH has been the subject of several research analyst reports. Weiss Ratings raised Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Zacks Research upgraded Delcath Systems from a “strong sell” rating to a “hold” rating in a research report on Tuesday.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. California State Teachers Retirement System purchased a new stake in shares of Delcath Systems during the second quarter worth about $26,000. Russell Investments Group Ltd. purchased a new position in shares of Delcath Systems during the third quarter valued at approximately $29,000. Tower Research Capital LLC TRC purchased a new position in Delcath Systems during the second quarter valued at $40,000. Legal & General Group Plc purchased a new position in shares of Delcath Systems in the 2nd quarter worth about $46,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Delcath Systems in the second quarter worth about $151,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

Delcath Systems Stock Up 3.2%

NASDAQ:DCTH opened at $13.52 on Friday. The business’s 50-day moving average price is $11.63 and its two-hundred day moving average price is $10.50. Delcath Systems has a twelve month low of $8.12 and a twelve month high of $13.74. The stock has a market cap of $466.71 million, a P/E ratio of 1,352.00 and a beta of 0.49.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.07. The firm had revenue of $24.99 million for the quarter, compared to analysts’ expectations of $23.51 million. Delcath Systems had a net margin of 0.62% and a return on equity of 0.51%. On average, equities research analysts expect that Delcath Systems will post -0.88 EPS for the current fiscal year.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.